, or pioglitazone, belongs in a class of medications called thiazolidinediones (TZDs). Taken orally and prescribed to treat Type 2 diabetic patients who are not insulin dependent, Actos is manufactured by Takeda Pharmaceuticals, a subsidiary of the Japan’s largest drug company Takeda Pharmaceutical Company Limited.

When first launched, Actos proved to be a very promising treatment: patients illustrated statistically significant reductions in blood glucose levels.  Additionally, , in conjunction with the U. S. based Eli Lilly